Current prostate biopsy protocols cannot reliably identify patients for focal therapy: Correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 4, 2010, Pages 401-407

  Quann, Philip ^a   Jarrard, David F ^b   Huang, Wei ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Biopsy; Focal therapy; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOPSY; BLOOD; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; PROSTATECTOMY; RISK FACTOR;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77955884359     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tareen B, Godoy G, Sankin A, Temkin S, Lepor H and Taneja SS. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int 2009;104(2):195-9.
2. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW and Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110:906-910.
3. Iczkowski KA, Hossain D, Torkko KC, Qian J, Lucia MS, Wheeler TM, Rewcastle JC and Bostwick DG. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 2008;71:1166-1171.
4. Stamey TA, McNeal JM, Wise AM and Clayton JL. Secondary cancers in the prostate do not determine PSA biochemical failure in untreated men undergoing radical retropubic prostatectomy. Eur Urol 2001; 39 Suppl 4:22-23.
5. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T and Bova GS. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15:559-565.
6. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361:1704-1706.
7. Lambert EH, Bolte K, Masson P and Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007;69: 1117-1120.
8. Marberger M. Energy-based ablative therapy of prostate cancer: high-intensity focused ultrasound and cryoablation. Curr Opin Urol 2007; 17:194-199.
9. Ahmed HU, Moore C and Emberton M. Minimallyinvasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 2009;18: 219-232.
10. Barqawi AB and Crawford ED. The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J 2007; 13:313-317.
11. Srigley JR. Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med 2006; 130:303-317.
12. Sehdev AE, Pan CC and Epstein JI. Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol 2001; 32:494-499.
13. Ochiai A, Troncoso P, Chen ME, Lloreta J and Babaian RJ. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol 2005; 174: 2164-2168, discussion 2168.
14. Hodge KK, McNeal JE, Terris MK and Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142:71-74; discussion 74-75.
15. Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M and Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000; 164:393-396.
16. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM and Slawin KM. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165:1554-1559.
17. Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K and Sofras F. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int 2007; 78:313-317.
18. Ravery V, Dominique S, Panhard X, Toublanc M, Boccon-Gibod L and Boccon-Gibod L. The 20-core prostate biopsy protocol--a new gold standard? J Urol 2008; 179:504-507.
19. Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A and Ozen H. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005; 173:1536-1540.
20. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M and Abenhaim L. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007;178:2260-2267.
21. Polascik TJ and Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 2009; 74:726-730.
22. Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW and Mouraviev V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 2009; 115:2104-2110.
23. Scales CD, Jr., Presti JC, Jr., Kane CJ, Terris MK, Aronson WJ, Amling CL and Freedland SJ. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. J Urol 2007; 178:1249-1252.
24. Barzell WE and Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. Urology 2007;70:27-35.
25. Andriole GL, Bullock TL, Belani JS, Traxel E, Yan Y, Bostwick DG and Humphrey PA. Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. Urology 2007;70:22-26.
26. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M and Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005;5:45.
27. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK and Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol 2009;35:537-546.
28. Huang D, Casale GP, Tian J, Lele SM, Pisarev VM, Simpson MA and Hemstreet GP, 3rd. Udpglucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer. Int J Cancer 2010;126:315-327.
29. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC and Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normalappearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10: 3465-3473.
30. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR and Mazumder A. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008; 68:152-160.
31. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM and Woodson KG. Gene promoter methylation in prostate tumorassociated stromal cells. J Natl Cancer Inst 2006;98:255-261.
32. Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM and Anderson KM. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci U S A 2003;100: 5401-5406.
33. Siegal JA, Yu E and Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545-2551.
34. Turkbey B, Albert PS, Kurdziel K and Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009;192:1471-1480.
35. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, HurdRE, Yen YF, Nelson SJ, Vigneron DB and Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008;68:8607-8615.
36. Wu C, Jordan K, Ratai E, Sheng J, Adkins C, De-Feo E, Jenkins B, Ying L, McDougal W and Cheng L. Metabolomic Imaging for Human Prostate Cancer Detection Sci Transl Med 2010;2:16-18.
37. Yang SY, Adelstein J and Kassis AI. Putative molecular signatures for the imaging of prostate cancer. Expert Rev Mol Diagn 2010;10:65-74.